A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007)
- DOI
- 10.3390/ph19050724
- Published
- 2026-05-02
- Container
- Pharmaceuticals
- Publisher
- MDPI AG
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3390/ph19050724,
title = {A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007)},
author = {Chenguang Wang and Chaoxin Zhou and Sheng Hou and Wenqiang Fan and Weizhu Qian and Yule Ren and Xiyuan Chen and Chenhong Pan and Qingcheng Guo and Huaizu Guo and Yajun Guo},
year = {2026},
journal = {Pharmaceuticals},
doi = {10.3390/ph19050724},
url = {https://doi.org/10.3390/ph19050724}
}RIS
TY - JOUR TI - A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007) AU - Chenguang Wang AU - Chaoxin Zhou AU - Sheng Hou AU - Wenqiang Fan AU - Weizhu Qian AU - Yule Ren AU - Xiyuan Chen AU - Chenhong Pan AU - Qingcheng Guo AU - Huaizu Guo AU - Yajun Guo PY - 2026 JO - Pharmaceuticals DO - 10.3390/ph19050724 UR - https://doi.org/10.3390/ph19050724 ER -
APA
Wang, C., Zhou, C., Hou, S., Fan, W., Qian, W., Ren, Y., Chen, X., Pan, C., Guo, Q., Guo, H., & Guo, Y. (2026). A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007). Pharmaceuticals. https://doi.org/10.3390/ph19050724
Source records
- crossref · retrieved 2026-09-27T10:41:36.782Z